HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $924 | -12.4% | 24,178 | -17.3% | 0.90% | -0.9% |
| Q2 2023 | $1,055 | -51.2% | 29,250 | -48.3% | 0.90% | -53.4% |
| Q1 2023 | $2,160 | -17.6% | 56,566 | +22.8% | 1.94% | -36.2% |
| Q4 2022 | $2,620 | -99.9% | 46,050 | -20.1% | 3.04% | +33.2% |
| Q3 2022 | $2,278,000 | -4.4% | 57,616 | -3.6% | 2.28% | +31.2% |
| Q1 2022 | $2,384,000 | -4.8% | 59,791 | -4.0% | 1.74% | -0.9% |
| Q4 2021 | $2,504,000 | -23.4% | 62,261 | -22.6% | 1.76% | -25.0% |
| Q3 2021 | $3,271,000 | -21.7% | 80,400 | -12.5% | 2.34% | -13.0% |
| Q2 2021 | $4,175,000 | -16.6% | 91,930 | -23.4% | 2.69% | -20.8% |
| Q1 2021 | $5,004,000 | -4.4% | 120,028 | -2.1% | 3.39% | -6.8% |
| Q4 2020 | $5,235,000 | +61.3% | 122,580 | -0.8% | 3.64% | +35.6% |
| Q3 2020 | $3,246,000 | -2.0% | 123,510 | -0.0% | 2.68% | -14.3% |
| Q2 2020 | $3,313,000 | +47.0% | 123,560 | -2.8% | 3.13% | +75.3% |
| Q1 2020 | $2,254,000 | 0.0% | 127,110 | 0.0% | 1.79% | 0.0% |
| Q4 2019 | $2,254,000 | +24.9% | 127,110 | +9.3% | 1.79% | +14.0% |
| Q3 2019 | $1,804,000 | -14.8% | 116,300 | -5.7% | 1.57% | -11.6% |
| Q2 2019 | $2,118,000 | -9.9% | 123,300 | -15.6% | 1.77% | -11.4% |
| Q1 2019 | $2,352,000 | -29.2% | 146,070 | -35.7% | 2.00% | -17.8% |
| Q4 2018 | $3,324,000 | +47.1% | 227,193 | +82.6% | 2.43% | +105.7% |
| Q3 2018 | $2,260,000 | -9.8% | 124,393 | -16.2% | 1.18% | -12.9% |
| Q2 2018 | $2,505,000 | -21.6% | 148,480 | -9.0% | 1.36% | -19.1% |
| Q1 2018 | $3,196,000 | +46.3% | 163,150 | +51.3% | 1.68% | +64.8% |
| Q4 2017 | $2,184,000 | +18.4% | 107,800 | +1.6% | 1.02% | +20.0% |
| Q3 2017 | $1,844,000 | +37.2% | 106,150 | +1.3% | 0.85% | +34.6% |
| Q2 2017 | $1,344,000 | -1.6% | 104,825 | -0.6% | 0.63% | +2.1% |
| Q1 2017 | $1,366,000 | +20.7% | 105,425 | -8.0% | 0.62% | +12.6% |
| Q4 2016 | $1,132,000 | -28.4% | 114,600 | -12.5% | 0.55% | -32.6% |
| Q3 2016 | $1,582,000 | +69.9% | 130,950 | +21.4% | 0.81% | +74.1% |
| Q2 2016 | $931,000 | -9.3% | 107,900 | -0.5% | 0.47% | -11.9% |
| Q1 2016 | $1,027,000 | +14.2% | 108,400 | +109.1% | 0.53% | +20.7% |
| Q4 2015 | $899,000 | +30.1% | 51,850 | +0.8% | 0.44% | +22.6% |
| Q3 2015 | $691,000 | -44.1% | 51,415 | -6.1% | 0.36% | -35.3% |
| Q2 2015 | $1,236,000 | +52.2% | 54,730 | -3.8% | 0.55% | +47.1% |
| Q1 2015 | $812,000 | +2.5% | 56,880 | -30.7% | 0.38% | -0.8% |
| Q4 2014 | $792,000 | +8.0% | 82,055 | +1.9% | 0.38% | +3.3% |
| Q3 2014 | $733,000 | -23.3% | 80,555 | -16.8% | 0.37% | -18.8% |
| Q2 2014 | $956,000 | -23.8% | 96,805 | -2.0% | 0.45% | -29.9% |
| Q1 2014 | $1,255,000 | -15.3% | 98,755 | -0.1% | 0.64% | -17.4% |
| Q4 2013 | $1,482,000 | +28.6% | 98,855 | -5.2% | 0.78% | +23.2% |
| Q3 2013 | $1,152,000 | +42.9% | 104,330 | +3.0% | 0.63% | +37.8% |
| Q2 2013 | $806,000 | – | 101,330 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |